bluebird bio(us:BLUE)
5.25
+7.58%
Updated on 2025-04-02
Open:4.86
Close:5.25
High:5.37
Low:4.82
Prev Close:4.88
Volume:860044.00
Turnover:4.39M
Turnover Ratio:8.78%
Shares:9.79M
MarketCap:51.40M
About bluebird bio
bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases. It also offers ZYNTEGLO or beti-cel and SKYSONA or eli-cel gene therapies. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Somerville, MA.
Company Name: bluebird bio
Address: 455 Grand Union Boulevard
Employees: 323
Fiscar Year: 12-31
IPO Date: 2013-06-19
Website: http://www.bluebirdbio.com
CIK: 1293971
View all SEC Filings
About
bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases. It also offers ZYNTEGLO or beti-cel and SKYSONA or eli-cel gene therapies. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Somerville, MA.
Address:455 Grand Union Boulevard
Website:http://www.bluebirdbio.com
Market Movers